Cyclerion Therapeutics (CYCN) Stock Analysis: AI Score & Alternative Data
CYCN alt-data: web traffic climbing, headcount lagging
Is Cyclerion Therapeutics a buy right now? The alternative data says hold. This CYCN stock analysis is built on the 25+ alternative data signals AltIndex tracks on Cyclerion Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 49/100: a Hold. The stock trades at $3.36 with a $16M market cap.
The bullish side of the 90-day ledger: web traffic up 38.2% to 3K monthly visits. The drag: headcount (according to LinkedIn) down 10.0% to 9 employees, and just 55% of employees report a positive business outlook. That tension is what keeps the score mid-range.
CYCN’s broader alt-data profile also covers X followers (347), and sentiment (100/100). Every signal links to its own page with full history, the CYCN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on CYCN is just below.
Cyclerion Therapeutics AI Stock Analysis
Cyclerion Therapeutics is a biopharmaceutical company that is focused on developing treatments for serious and rare diseases. The company employs an innovative approach to discovering and developing treatments based on the modulation of cyclic guanosine monophosphate (cGMP).
Analysis generated October 1, 2026.
Recent Cyclerion Therapeutics Stock Alerts
|
Cyclerion Therapeutics | September 8 Price is down by -21.2% in the last 24h. |
|
Cyclerion Therapeutics | September 4 Price is down by -11.5% in the last 24h. |
|
Cyclerion Therapeutics | September 3 Price is up by 9.5% in the last 24h. |
|
Cyclerion Therapeutics | September 2 Price is up by 7.9% in the last 24h. |
Cyclerion Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 3K | 38.2% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 9 | 10.0% | |
| Employee Recommend | 100 | 0% | |
| Business Outlook | 55 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 85.7% | |
| Stocktwits Mentions | 0 | 100.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 8K | 1.2% | |
| X Followers | 347 | 1.4% |
About Cyclerion Therapeutics (CYCN)
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
| Price | $3.36 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $16M |
| Year Range | $1 – $6 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Cyclerion Therapeutics News
View more → |
Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsightOctober 7 - PRNewswire |
Gastrointestinal Collaboration and Licensing Agreements Benchmark Report 2026: Access to Structured Analysis of 432 Deals Signed Since 2016 - Finance, Indications, Modalities, Stages of DevelopmentMay 19 - GlobeNewswire |
See Cyclerion Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for CYCN, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREECyclerion Therapeutics Earnings & Financial Performance
View all earnings →Cyclerion Therapeutics Insider Trading Activity
View all →| Slate Path Capital LP filed to sell 0 shares at $0.0. Nov 21 '24 |
Cyclerion Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Cyclerion Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Allarity TherapeuticsALLR |
$0.99 0.8% | $16M | 56 |
 |
Pasithea TherapeuticsKTTA |
$0.47 6.0% | $16M | 48 |
 |
Tscan TherapeuticsTCRX |
$0.24 4.3% | $16M | 52 |
 |
Dare BioscienceDARE |
$0.77 0.2% | $15M | 61 |
 |
Vyome HoldingsHIND |
$2.09 3.0% | $15M | 47 |
Explore Cyclerion Therapeutics Data
Frequently Asked Questions: Cyclerion Therapeutics (CYCN)
Cyclerion Therapeutics has an AltIndex AI Score of 49/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
49/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Cyclerion Therapeutics (CYCN) stock is $3.36 with a market cap of $16M.
As of today, Cyclerion Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Cyclerion Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Cyclerion Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The CYCN stock price chart above shows Cyclerion Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Cyclerion Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Cyclerion Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
